Mar Tormo Díaz-rekin lankidetzan egindako argitalpenak (24)

2024

  1. EEG before chimeric antigen receptor T-cell therapy and early after onset of immune effector cell-associated neurotoxicity syndrome

    Clinical Neurophysiology, Vol. 163, pp. 132-142

  2. Incidence and clinical correlates of NFE2 mutations in myeloid neoplasms

    British Journal of Haematology

2023

  1. SARS-CoV-2-reactive antibody waning, booster effect and breakthrough SARS-CoV-2 infection in hematopoietic stem cell transplant and cell therapy recipients at one year after vaccination

    Bone Marrow Transplantation, Vol. 58, Núm. 5, pp. 567-580

2022

  1. Booster effect after SARS-CoV-2 vaccination in immunocompromised hematology patients with prior COVID-19

    Blood Advances

  2. Multi-body-site colonization screening cultures for predicting multi-drug resistant Gram-negative and Gram-positive bacteremia in hematological patients

    BMC Infectious Diseases, Vol. 22, Núm. 1

  3. SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders

    Journal of hematology & oncology, Vol. 15, Núm. 1, pp. 54

2021

  1. Myelodysplastic syndromes with 20q deletion: incidence, prognostic value and impact on response to azacitidine of ASXL1 chromosomal deletion and genetic mutations

    British Journal of Haematology, Vol. 194, Núm. 4, pp. 708-717

2020

  1. Clinical significance of Pneumocystis jirovecii DNA detection by real-time PCR in hematological patient respiratory specimens

    Journal of Infection

  2. Early adjustment of empirical antibiotic therapy of bloodstream infections on the basis of direct identification of bacteria by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and Gram staining results

    Journal of Infection and Chemotherapy, Vol. 26, Núm. 9, pp. 963-969

  3. Host immune genetic variations influence the risk of developing acute myeloid leukaemia: results from the NuCLEAR consortium

    Blood Cancer Journal, Vol. 10, Núm. 7

  4. Impact of clinical features, cytogenetics, genetic mutations, and methylation dynamics of CDKN2B and DLC-1 promoters on treatment response to azacitidine

    Annals of Hematology, Vol. 99, Núm. 3, pp. 527-537

2019

  1. Cytomegalovirus DNAemia in patients with de novo acute myeloid leukemia undergoing cytotoxic chemotherapy

    Leukemia and Lymphoma

  2. Pulmonary cytomegalovirus (CMV) DNA shedding in allogeneic hematopoietic stem cell transplant recipients: Implications for the diagnosis of CMV pneumonia

    Journal of Infection, Vol. 78, Núm. 5, pp. 393-401

  3. Synergistic antioncogenic activity of azacitidine and curcumin in myeloid leukemia cell lines and patient samples

    Anticancer Research, Vol. 39, Núm. 9, pp. 4757-4766

2018

  1. Primary prophylaxis of invasive fungal infections with posaconazole or itraconazole in patients with acute myeloid leukaemia or high-risk myelodysplastic syndromes undergoing intensive cytotoxic chemotherapy: A real-world comparison

    Mycoses, Vol. 61, Núm. 3, pp. 206-212

  2. Therapy-related acute myeloid leukemia developing 14 years after allogeneic hematopoietic stem cell transplantation, from a persistent R882H-DNMT3A mutated clone of patient origin

    Experimental and Molecular Pathology, Vol. 105, Núm. 1, pp. 139-143

2011

  1. An XRCC1 polymorphism is associated with the outcome of patients with lymphoma undergoing autologous stem cell transplant

    Leukemia and Lymphoma, Vol. 52, Núm. 7, pp. 1249-1254

  2. Diagnostic accuracy and potential clinical value of the LightCycler SeptiFast assay in the management of bloodstream infections occurring in neutropenic and critically ill patients

    International Journal of Infectious Diseases, Vol. 15, Núm. 5

2005

  1. Guillain-Barré syndrome associated with cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation

    Transplant Infectious Disease, Vol. 7, Núm. 2, pp. 93-96

  2. Impact of different strategies of second-line stem cell harvest on the outcome of autologous transplantation in poor peripheral blood stem cell mobilizers

    Bone Marrow Transplantation, Vol. 36, Núm. 10, pp. 847-853